BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Federal Trade Commission
US Department of Justice
US Army
Queensland Health

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,731,000

« Back to Dashboard

Summary for Patent: 5,731,000

Title: Stabilized pharmaceutical composition containing bupropion
Abstract:This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
Inventor(s): Ruff; Michael David (Greenville, NC), Kalidindi; Sanyasi Raju (Edison, NJ), Sutton, Jr.; Joel Elmore (Greenville, NC)
Assignee: Glaxo Wellcome Inc. (Rtp, NC)
Application Number:08/586,916
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,731,000

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9315856Jul 30, 1993
PCT Information
PCT FiledJuly 29, 1994PCT Application Number:PCT/GB94/01642
PCT Publication Date:February 09, 1995PCT Publication Number: WO95/03791

International Patent Family for Patent: 5,731,000

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria232383► Subscribe
Australia698883► Subscribe
Australia7235294► Subscribe
Canada2168364► Subscribe
Germany69432121► Subscribe
Denmark0711154► Subscribe
European Patent Office0711154► Subscribe
Spain2189804► Subscribe
United Kingdom9315856► Subscribe
Hong Kong1004186► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Johnson and Johnson
Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus